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ABSTRACT
Background Non- invasive biomarkers for the assessment 
of disease severity in idiopathic pulmonary fibrosis (IPF) 
are urgently needed. Calprotectin belongs to the S-100 
proteins produced by neutrophils, which likely contribute 
to IPF pathogenesis. Calprotectin is a well- established 
biomarker in inflammatory bowel diseases. In this cross- 
sectional study, we aimed to establish the potential role 
of calprotectin as a biomarker in IPF. Specifically, we 
hypothesised that patients with IPF have higher serum 
calprotectin levels compared with healthy controls, and 
that calprotectin levels are associated with disease 
severity.
Methods Blood samples were obtained from healthy 
volunteers (n=26) and from two independent IPF cohorts 
(derivation cohort n=26, validation cohort n=66). Serum 
calprotectin levels were measured with a commercial 
kit adapted for that purpose and compared between 
healthy controls and patients with IPF. Clinical parameters, 
including forced vital capacity, diffusing capacity for carbon 
monoxide (DLCO) and the Composite Physiologic Index 
(CPI), were correlated with calprotectin serum levels.
Results The IPF derivation cohort showed increased 
serum calprotectin levels compared with healthy controls 
(2.47±1.67 vs 0.97±0.53 µg/mL, p<0.001). In addition, 
serum calprotectin levels correlated with DLCO% predicted 
(r=−0.53, p=0.007) and with CPI (r=0.66, p=0.007). These 
findings were confirmed in an independent IPF validation 
cohort.
Conclusion Serum calprotectin levels are significantly 
increased in patients with IPF compared with healthy 
controls and correlate with DLCO and CPI. Calprotectin 
might be a potential new biomarker for disease severity 
in IPF.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is the proto-
type of severe fibrosing interstitial lung diseases 
(ILD).1 The progressive loss of alveolar epithe-
lial cells (AEC) in IPF induces abnormal lung 
fibroblast accumulation and extracellular matrix 
(ECM) deposition,2 leading to progressive loss 
of pulmonary function in affected patients.3 
Two antifibrotic drugs are available to slow 
down disease progression.4 5 The assessment of 
disease severity and progression are important 
to evaluate the natural course of disease, predict 
prognosis and estimate treatment response in 
the individual patient. Pulmonary function tests 
(PFT) are the standard to assess disease progres-
sion. However, PFTs have important weaknesses, 
including intrapatient variability, poor sensitivity 
to change, as well as possible difficulties in acqui-
sition (eg, in patients with advanced disease). 
Alternative non- invasive biomarkers that capture 
changes in disease severity and progression of 
IPF are urgently needed for clinical practice and 
to optimise future clinical trial design.6
Calprotectin is an heterodimer complex that 
belongs to the S-100 family and has been inves-
tigated as biomarker and treatment target in 
various diseases.7 This complex is formed by 
S100A8 and S100A9 subunits, also mentioned 
in the literature as calgranulin A and B, MRP8 
and MRP14 or 27E10 antigen.8 Calprotectin is 
expressed in several immune cells, including 
macrophages and monocytes, as well as neutro-
phils,9 and belongs to the damage- associated 
molecular pattern proteins (DAMP), an 
important group of proteins of the innate 
immune system that promote inflammatory 
Key message
 ► We investigated the relevance/association of serum 
calprotectin levels with the disease severity of pa-
tients with idiopathic pulmonary fibrosis (IPF).
 ► Serum calprotectin levels are significantly higher in 
patients with IPF compared with healthy controls 
and correlate with disease severity in two indepen-
dent IPF cohorts.
 ► This is the first study demonstrating a potential role 
of serum calprotectin as a biomarker of disease se-
verity in patients with IPF.
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responses.10 Involvement in the inflammatory and the innate 
immune response have been described.11 In clinical routine, 
calprotectin is a well- established biomarker for disease 
activity in inflammatory bowel diseases (IBD).12 Further-
more, calprotectin has already been investigated in fibrotic 
diseases such as systemic sclerosis13 and skin fibrosis.14
Although the role of inflammation is controversial in 
IPF,15 some previous observations support the idea of 
a moderate role of inflammation in IPF. For example, 
neutrophil count is elevated in bronchoalveolar lavage 
fluid (BALF) from patients with IPF which correlates 
as well with mortality.16 BALF levels of calprotectin 
subunits (ie, S100A9) are higher in IPF compared with 
other ILDs and healthy controls.17–19 Collectively, these 
findings underline the potential role of calprotectin as 
a biomarker for disease activity and severity in fibrotic 
diseases, specifically IPF.
We hypothesised that serum calprotectin levels are 
higher in patients with IPF than in healthy controls, 
and correlate with disease severity in patients with IPF. 
We tested our hypotheses in a derivation cohort of Swiss 
patients with IPF and validated our findings in an inde-
pendent cohort of Spanish patients with IPF.
METHODS
Study participants and measurements
Healthy controls and Swiss IPF derivation cohort
Blood serum samples from 26 healthy controls without 
known respiratory disease and normal pulmonary func-
tion, and from 26 patients with IPF were collected within 
the prospective Swiss IIP cohort study in Bern. Patients 
with IPF were diagnosed according to the American 
Thoracic Society/European Respiratory Society/Japa-
nese Respiratory Society/Latin American Thoracic 
Association (ATS/ERS/JRS/ALAT) guidelines.3 Clin-
ical features such as age, sex, body mass index, smoking 
(pack- years) and PFTs were collected.
The Composite Physiologic Index (CPI), which reflects 
the morphological extent of pulmonary fibrosis, was calcu-
lated by using forced vital capacity (FVC), forced expira-
tory volume in 1 s (FEV1) and diffusing capacity for carbon 
monoxide (DLCO), as previously described.20
Spanish IPF validation cohort
The validation cohort consisted of 66 patients with 
IPF diagnosed at the ILD Unit of Bellvitge University 
Hospital, in Barcelona. Patients’ diagnosis was made 
following the ATS/ERS/JRS/ALAT guidelines.3 In addi-
tion, patient’s characteristics and PFTs were recorded. All 
patients signed written informed consent before inclu-
sion in both cohorts.
Calprotectin measurement
Peripheral blood samples were obtained from all partici-
pants and serum fraction was separated by centrifugation 
at 2000 x g for 15 min within an hour of blood extraction 
before storage at −20°C until use. All available samples from 
both cohorts were analysed in the Centre of Laboratory 
Medicine at the Bern University Hospital, Switzerland.
A commercially available enzyme- linked chemilumines-
cent immunoassay (CLIA) kit for faecal calprotectin (701350, 
QuantaFlash, INOVA Diagnostics, San Diego, California, 
USA) was adapted to measure circulating calprotectin in 
serum samples. Serum concentrations of calprotectin were 
converted from µg/g stool into µg/mL by multiplying the 
values by a factor of 0.023. Using a receiver operating charac-
teristic (ROC) analysis in our Swiss cohort, a cut- off of 1.133 
µg/mL calprotectin resulted in a sensitivity of 76.92% (95% 
CI 57.95% to 88.97%) and a specificity of 80.77% (95% CI 
62.12% to 91.49%).
Patient and public involvement
Patients and the public were not involved in the design and 
conduct of this study, choice of outcome measures, nor 
recruitment. The results of this study will not be dissemi-
nated to the participants and linked communities.
Statistical analysis
Clinical features and serum calprotectin levels were reported 
as mean (SD) or median (IQR) depending on the distribu-
tion of the variables assessed by histograms.
Wilcoxon signed- rank tests were used to compare 
calprotectin levels between two groups, Spearman’s 
correlation was used for unadjusted correlation between 
serum calprotectin levels and continuous clinical vari-
ables. Multivariable linear regression models were used to 
determine an independent relationship between serum 
calprotectin levels and IPF severity. Calprotectin values 
were log transformed to account for the non- normal 
distribution, and potential confounders of conceptual 
importance (eg, age, sex or smoking) or a relevant 
unadjusted correlation with serum calprotectin levels 
(predictor) and IPF severity (outcome) were included 
in the models. The coefficient of determination (R2) 
was used to assess the percent of variance in calprotectin 
that was explained by the linear models. The Akaike 
information criterion was used to compare the model fit. 
Kaplan- Meier curves were used to illustrate the associa-
tion of serum calprotectin levels with survival, HRs from 
Cox proportional hazard models and ORs from logistic 
regression models were used to quantify the relationship 
between calprotectin levels, overall and 1- year survival. A 
two- sided p<0.05 indicated statistical significance for all 
comparisons. Data were analysed using R 3.6.0 (R Foun-
dation for Statistical Computing, Vienna, Austria)
RESULTS
Serum calprotectin levels in healthy controls and in patients 
with IPF
Clinical features of all three groups of participants 
included in this study are shown in table 1. More than 
half of healthy controls (54%) were male with an average 
age of 47.6 years (±12) and 4.5 (0–15) smoked pack- years. 
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Patients with IPF from the derivation and the valida-
tion cohort were predominantly male, and older than 
healthy controls (derivation cohort 69.6±11.5, validation 
cohort 71.3±7.1) with a more important smoking history. 
As expected, healthy controls showed normal values in 
PFTs; while patients with IPF had impaired pulmonary 
function parameters. The patients in the Swiss derivation 
cohort showed lower FVC % predicted than patients in 
the Spanish validation cohort (62.4±16.1 vs 81.7%±17.9% 
predicted, respectively).
The CLIA analyses of calprotectin revealed significantly 
higher serum calprotectin levels in patients with IPF 
compared with healthy controls (2.47±1.67 vs 0.97±0.53 
µg/mL, p<0.001, figure 1A). After the adjustment for 
confounding factors such as age and sex, serum calpro-
tectin levels remained 1.3 µg/mL higher in patients with 
IPF (95% CI 0.29 to 2.31 µg/mL, p=0.01) compared with 
healthy controls (online supplemental figure 1).
Correlation of serum calprotectin levels with IPF disease 
severity in the derivation cohort
In the Swiss IPF derivation cohort, serum calprotectin 
levels showed a moderate to strong negative and positive 
correlation with DLCO% predicted and CPI, respectively 
(r=−0.53, and r=0.66, respectively, both p<0.01) (table 2 
and figure 2A,B).
In the adjusted models accounting for potential 
confounding by age, sex and smoked pack- years, 
DLCO% predicted and CPI both remained significantly 
correlated with serum calprotectin levels in patients with 
IPF (table 3).
Levels of serum calprotectin levels and correlation with IPF 
disease severity in the validation cohort
To validate our findings from the Swiss IPF cohort, we 
repeated calprotectin measurements in serum samples 
Table 1 Baseline characteristics of healthy controls and patients with IPF
  Healthy controls (n=26)
Patients with IPF
Derivation cohort (n=26) Validation cohort (n=66)
Sex, men 14 (54%) 24 (92%) 59 (89%)
Age, years 47.6 (12) 69.6 (11.5) 71.3 (7.1)
BMI, kg/m2 24.4 (3.4) 26.2 (3.1) 28.6 (3.6)
Ever- smokers 14 (54%) 20 (77%) 47 (71%)
Pack- years 4.5 (0–15) 30 (20–40) 20 (0–35)
Diabetes 17 (26%)
Dyslipidaemia 29 (44%)
DLCO, % predicted 89.4 (11.1) 44.3 (15.2) 53.7 (16.9)
FVC, % predicted 101.8 (10.4) 62.4 (16.1) 81.7 (17.9)
FEV1, % predicted 95.9 (10.7) 73.5 (11) 83.6 (17.2)
CPI 11.6 (8.9) 50.5 (11.2) 41.0 (14.2)
Calprotectin, µg/mL 0.89 (0.57–1.12) 2.16 (1.12–2.85) 2.90 (1.60–3.78)
Data expressed in number (percentage), mean (SD) or median (IQR).
BMI, body mass index; CPI, Composite Physiological Index; DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume 
in one second; FVC, forced vital capacity; IPF, idiopathic pulmonary fibrosis.
Figure 1 Distribution of serum calprotectin levels in patients with IPF and in healthy controls. (A) healthy controls (green) 
and patients with IPF (orange) in the derivation cohort. (B) Patients with IPF from the validation cohort. Dashed lines indicate 
mean. IPF, idiopathic pulmonary fibrosis.
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from an independent Spanish IPF cohort (baseline char-
acteristics shown in table 1). Increased serum calpro-
tectin levels were confirmed in the IPF validation cohort 
(figure 1B and online supplemental figure 1).
Correlation of serum calprotectin levels with clin-
ical features of the validation cohort are shown in 
table 2. Without adjustment for potential confounders, 
the correlation between serum calprotectin levels and 
measurements of disease severity was weak (DLCO 
r=−0.23, p=0.06; and CPI r=0.22, p=0.08) (table 2 and 
figure 2C,D). After adjustment for age, sex, smoking 
status and treatment in individual multivariable linear 
regression models (table 4), DLCO% predicted and CPI 
were independently associated with serum calprotectin 
levels in the Spanish IPF cohort.
Levels of serum calprotectin and mortality
In the derivation cohort, patients with calprotectin 
levels above the highest quartile (≥2.85 µg/mL) had 
significantly worse survival compared with patients with 
calprotectin levels (HR 6.10, 95%CI 1.45 to 25.6, p=0.01) 
(online supplemental figure 2A). The relationship 
between high calprotectin and mortality remained signif-
icant after adjustment for age and sex (HR 4.59, 95% CI 
1.10 to 19.1, p=0.04).
Table 2 Unadjusted correlation of baseline characteristics and disease severity with calprotectin serum levels in the three 
study groups
Calprotectin levels Healthy controls Derivation IPF cohort Validation IPF cohort
Variables r P value r P value r P value
Sex, men 0.03 0.81 0.15
Age, years 0.17 0.39 −0.02 0.91 −0.16 0.20
BMI, kg/m2 0.50 0.009 0.12 0.63 0.01 0.94
Ever- smokers 0.60 0.35 0.08
Pack- years 0.03 0.88 0.62 0.07 0.14 0.28
DLCO, % predicted 0.31 0.12 −0.53 0.007 −0.23 0.06
FVC, % predicted 0.12 0.56 0.02 0.90 −0.13 0.29
FEV1, % predicted 0.13 0.54 0.33 0.20 −0.03 0.78
CPI −0.31 0.13 0.66 0.007 0.22 0.08
BMI, body mass index; CPI, Composite Physiological Index; DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume 
in 1 s; FVC, forced vital capacity; IPF, idiopathic pulmonary fibrosis; r, correlation coefficient.
Figure 2 Unadjusted correlation between calprotectin levels and predicted DLCO and CPI in the derivation (A, B) and the 
validation cohort (C, D). CPI, Composite Physiological Index; DLCO, diffusing capacity for carbon monoxide.
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In the validation cohort, the highest calprotectin 
quartile (≥3.78 µg/mL) did not significantly discrimi-
nate long- term mortality (HR 1.54, 95%CI 0.53 to 4.44, 
p=0.43). However, calprotectin levels were significantly 
associated with 1- year survival, with an OR for mortality 
per 1 µg/mL increase of 1.46 (95% CI 1.01 to 2.16, 
p=0.04) (online supplemental figure 2B). This relation-
ship remained significant after adjustment for age and 
sex (OR 1.53, 95%CI 1.03 to 2.41, p=0.04).
DISCUSSION
Our cross- sectional study including two independent 
European IPF cohorts shows that patients with IPF have 
higher serum calprotectin levels compared with healthy 
controls, and that calprotectin levels correlate with 
disease severity in IPF. These findings suggest a poten-
tial role of calprotectin as a blood biomarker for disease 
severity in IPF.
The need of new simple, reliable, valid and preferably 
non- invasive biomarkers in fibrotic lung diseases is undis-
putable. Over the last decade, our understanding of IPF 
pathogenesis has grown substantially, and anti- fibrotic 
drugs have been approved for treatment. However, estab-
lishing valid biomarkers for the assessment of disease 
severity and progression remains challenging.
PFTs are widely available and well- validated to monitor 
the course of fibrotic ILDs, particularly in the setting of 
clinical trials.21 However, pulmonary function decline 
only indirectly reflects disease progression, and the high 
noise- to- signal ratio in the individual patient makes it 
challenging to evaluate disease progression from FVC 
and DLCO trajectories.21–23 Very frequent (even daily) 
FVC measurements might improve this poor noise- to- 
signal ratio but have not been established in clinical 
practice yet. Some patients with advanced disease have 
difficulties to perform spirometry and DLCO assessment, 
and alternative methods to assess pulmonary function 
are emerging.24
Multidimensional indices including demographics and 
multiple pulmonary function parameters are valid tools 
to predict radiological disease severity and mortality in 
IPF.25 A recent study confirmed the prognostic validity of 
isolated predicted DLCO% measurement and the multi-
dimensional CPI,26 which we used to estimate disease 
severity in our study population.
Current antifibrotic drugs have improved IPF treatment 
substantially over the last years. Therefore, the effective-
ness of potential new drugs needs to be investigated on 
the background of currently available antifibrotic medi-
cations. This highlights the need for easy- to- measure 
clinical trial outcomes that are highly sensitive to change. 
Blood- based biomarkers such as calprotectin might 
improve outcome assessment in future clinical trials 
and in individual patients in addition to currently used 
pulmonary function measurements.
The potential of calprotectin as a biomarker in IPF 
is underlined by previous studies. Higher levels of the 
S100A9 subunit of calprotectin have been detected in 
BALF from patients with IPF compared with patients 
with sarcoidosis and healthy controls, with BALF S100A9 
levels correlating with FVC and DLCO.18 19 The S100A9 
subunit of calprotectin might also be involved in other 
fibrotic ILDs. Greater levels of the S100A9 subunit have 
also been reported in BALF from patients with idio-
pathic non- specific interstitial pneumonia with fibrotic 
pattern,27 suggesting a link between the this subunit and 
fibrosis in general.
However, the exact source as well as the role of elevated 
serum calprotectin in patients with IPF remain unclear. 
Calprotectin is produced by neutrophils and a correla-
tion between the amount of neutrophils in BALF from 
patients with IPF with the levels of S100A9 subunit of 
calprotectin has been described.17 18 In addition, BALF 
neutrophilia is associated with poor prognosis in IPF,16 
and other neutrophil- associated proteins have been 
described as markers of disease severity in patients with 
Table 3 Multivariable linear regression models for the adjusted correlation of calprotectin with disease severity in the 
derivation cohort
Log (calprotectin)
Adjusted for age, sex, smoked pack- years
Coefficient (95% CI) P value Adjusted R2
DLCO, % predicted −0.05 (−0.09 to −0.01) 0.02 0.74
CPI 0.08 (0.03 to 0.12) 0.01 0.85
CPI, Composite Physiological Index; DLCO, diffusing capacity for carbon monoxide; R2, coefficient of determination.
Table 4 Multivariable linear regression models for the adjusted correlation of calprotectin with disease severity in the 
validation cohort
Log (calprotectin)
Adjusted for age, sex, smoking status and pirfenidone treatment
Coefficient (95% CI) P value Adjusted R2
DLCO, % predicted −0.01 (−0.002 to −0.020) 0.01 0.16
CPI 0.014 (0.003 to 0.024) 0.01 0.17
CPI, Composite Physiological Index; DLCO, diffusing capacity for carbon monoxide; R2, coefficient of determination.
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IPF.28 In analogy, other chronic lung diseases showing 
increased neutrophils, such as COPD, plasma calpro-
tectin levels were associated with neutrophil granulocyte 
count and even mortality.29
Calprotectin has been previously associated with exac-
erbation and lung functional decline in inflammatory 
lung diseases such as cystic fibrosis.30 However, the role 
of inflammation in IPF remains controversial.15 Acti-
vation and development of lung fibrosis may involve 
several inflammatory mechanisms, but the strong effect 
of transforming growth factor-β (TGF-β) during fibrosis 
is thought to limit the role of inflammation in IPF.31 
Furthermore, previous use of anti- inflammatory and 
immunosuppressive treatments have been unsuccessful 
and even harmful in patients with IPF.32
Nevertheless, these therapeutic failures do not exclude 
a relevant role of inflammation in the IPF disease 
process. Although inflammatory cells are not a predom-
inant finding in the histopathology of IPF, they might 
regulate lung fibroblasts behaviour and ECM deposi-
tion.33 Involvement of the S100A8 and S100A9 subunits 
of calprotectin in the fibrotic process and activation was 
previously suggested.14 In lung fibrosis, S100A9 activates 
proliferation of lung fibroblasts and induces produc-
tion of proinflammatory cytokines in vitro through the 
receptor for advanced glycation endproducts (RAGE).34 
RAGE is a multiligand receptor of S-100 family proteins 
highly expressed in the AECs and is responsible for accel-
eration of the immune and inflammatory responses.35 
Furthermore, the soluble isoform of RAGE might exert 
a protective response against proinflammatory signals of 
calprotectin by interfering with receptor binding,36 which 
is downregulated in patients with IPF.37 Thus, the pres-
ence of calprotectin in BALF and serum and the down-
regulation of inhibitory proteins suggest the involvement 
of calprotectin in the pathogenesis of IPF. However, with 
our current study we cannot answer the pathogenetic 
role of calprotectin.
The present study has some limitations. Our healthy 
controls were younger, and less frequently men and 
smokers, which likely confounds the higher calprotectin 
levels in IPF compared with those controls. We adjusted 
our analysis for these differences, to account for poten-
tial confounding. Unlike to previous reports, we did 
not assess neutrophils in blood or BALF to confirm a 
relationship of serum calprotectin with neutrophilia. 
Furthermore, the cross- sectional design of this study does 
not allow definite conclusions on a causal relationship 
between calprotectin and IPF progression; further studies 
are needed to assess calprotectin as a marker of disease 
progression, and its prognostic role either in isolation or 
in combination with clinical and functional parameters. 
By establishing an age, sex and exposure independent 
association of serum calprotectin with disease severity 
in a cohort of patients with IPF with advanced disease 
and a second cohort with less severe disease, we ensure 
generalisability of our findings to most IPF cohorts. This 
pilot project did not aim for integration of calprotectin 
serum measurements in clinical practice, but demon-
strates feasibility and provides prognostic validity of this 
biomarker in patients with IPF.
In conclusion, we demonstrate that serum calpro-
tectin levels are significantly higher in patients with IPF 
compared with healthy controls and show a relevant 
correlation of calprotectin with disease severity measured 
by DLCO and CPI with confirmation of these findings in 
an independent validation cohort. Taken together with 
findings from previous studies we propose serum calpro-
tectin as a new biomarker for disease severity assessment 
in IPF.
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